4D Molecular Therapeutics (NASDAQ: FDMT) revenue
4D Molecular Therapeutics reported revenue of $85.2m for fiscal 2025, 230,194.6% more than in fiscal 2024 ($0.0m). Since fiscal 2019 its revenue has grown by 1,119.7%, an average growth of 51.7% a year.
Fiscal 2025 is the highest of the 7 fiscal years on record for 4D Molecular Therapeutics. The biggest drop was in fiscal 2024, −99.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $85.2m | +230,194.6% | −$159.5m | −187.2% |
| 2024 | $0.0m | −99.8% | −$187.8m | −507,678.4% |
| 2023 | $20.7m | +562.3% | −$112.9m | −544.6% |
| 2022 | $3.1m | −82.7% | −$110.0m | −3,516.5% |
| 2021 | $18.0m | +32.5% | −$71.3m | −395.5% |
| 2020 | $13.6m | +94.8% | −$56.7m | −416.3% |
| 2019 | $7.0m | — | −$50.8m | −726.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
4D Molecular Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, 4D Molecular Therapeutics ranks 295th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; 4D Molecular Therapeutics, 230,194.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 293rd | Cytokinetics | $88.0m | 376.6% |
| 294th | Delcath Systems | $85.2m | 129.1% |
| 295th | 4D Molecular Therapeutics | $85.2m | 230,194.6% |
| 296th | ARS Pharmaceuticals | $84.3m | −5.5% |
| 297th | Nurix Therapeutics | $84.0m | 54.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of 4D Molecular Therapeutics
- How much revenue did 4D Molecular Therapeutics make in fiscal 2025?
- 4D Molecular Therapeutics reported revenue of $85.2m for fiscal 2025, compared with $0.0m in fiscal 2024.
- How much has the revenue of 4D Molecular Therapeutics grown?
- Between fiscal 2019 and fiscal 2025 it went from $7.0m to $85.2m: 1,119.7% more, an average growth of 51.7% a year.
- What was the best year for revenue at 4D Molecular Therapeutics?
- Of its last 7 fiscal years, fiscal 2025, with $85.2m.
- Where does 4D Molecular Therapeutics rank in its sector by revenue?
- It ranks 295th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for 4D Molecular Therapeutics come from?
- From the annual report (Form 10-K) that 4D Molecular Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that 4D Molecular Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on 4D Molecular Therapeutics: the 4D Molecular Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.